Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study
- 151 Downloads
Background and Aims
The relationship between insulin resistance and post-ERCP pancreatitis (PEP) is not known. We aimed to determine the relation between pre-ERCP insulin resistance and risk of PEP, and to evaluate the relationship of insulin resistance with well-established risk factors for PEP.
Consecutive patients who underwent ERCP with the diagnosis of choledocolithiasis between January and December 2013 were enrolled in this prospective study. Pre-procedural insulin resistance state and other risk factors were evaluated according to PEP development.
Pancreatitis developed in 16 (11.3 %) of 141 ERCP procedure. Homeostasis model assessment of insulin resistance (HOMA-IR) levels was found statistically significantly higher in patients who developed PEP than the ones who did not (3.37 ± 0.8 vs. 2.38 ± 1.4, p < 0.001). Common bile duct (CBD) diameter of the patients developing PEP was found significantly lower than the non-PEP group (10.1 ± 4 vs. 13.4 ± 4.5 mm, p = 0.01). Mean procedure time was 33.5 min in PEP group and 27.9 min in non-PEP group (p = 0.006). HOMA-IR (OR 2.39), procedure time (OR 1.15), and CBD diameter (OR 0.82) were independent predictors of PEP development.
The presence of insulin resistance is an important risk factor for PEP, and these data can be used as a considerable clue to predict the risk of PEP before ERCP and to decrease related morbidity.
KeywordsPost-ERCP pancreatitis Insulin resistance HOMA-IR
Special thanks to biostatistician Sinan IYIGUN for advising and performing advanced statistical analyses.
Compliance with ethical standards
Conflict of interest
We confirm that there are no financial or other relations that could lead to a conflict to interest.
- 1.Freeman ML. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP J Pancreas. 2002;3:169–176.Google Scholar
- 12.Badalov N, Tenner S, Baillie J. The Prevention, recognition and treatment of post-ERCP pancreatitis. JOP J Pancreas. 2009;10:88–97.Google Scholar
- 13.Sahakian AB, Buxbaum JL, Van Dam J. Prevention and management of Post-ERCP Pancreatitis. JOP J Pancreas. 2014;15:544–551.Google Scholar
- 14.Testoni PA. Unresolved issues about post-ERCP pancreatitis: an overview. JOP J Pancreas. 2002;3:156–161.Google Scholar
- 15.Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP J Pancreas. 2002;3:162–168.Google Scholar
- 21.Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640–1645.CrossRefPubMedGoogle Scholar
- 32.Katsinelos P, Lazaraki G, Chatzimavroudis G, et al. Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2014;27:65–72.Google Scholar
- 33.Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. J Pancreas. 2002;3:195–201.Google Scholar
- 34.Hernández Garcés HR, Almeida Linnet A, Abreu Vázquez MDR, et al. Risk factors associated with the development of hyperamylasemia and post-ERCP pancreatitis in the Cuban National Institute. Rev Gastroenterol Perú Órgano Soc Gastroenterol Perú. 2014;34:127–132.Google Scholar
- 35.Leghari A, Ghazanfar S, Qureshi S, et al. Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centre. J Coll Phys Surg Pak. 2013;23:620–624.Google Scholar
- 44.Kumar N, Gergi MA, Thompson CC. Obesity is an independent risk factor for post-ERCP pancreatitis: results of a nationwide database analysis [Abstract]. Gastrointest Endosc. 2012;75:AB142.Google Scholar